New Jersey class action settlements

Metformin Marketing and Sales Practices Settlement

The defendants falsely advertised their generic metformin drugs as equivalent to Glucophage and Glucophage XR, but the drugs were contaminated with NDMA and did not meet FDA standards. Consumers and businesses paid for drugs they would not have purchased had they known the truth. The defendants deny wrongdoing.

EMM Loans Data Breach Settlement

EMM Loans was the target of a cyberattack on its computer systems in February 2024. The attack resulted in unauthorized access to files containing personal information including names, Social Security numbers, driver's license numbers, and passport numbers. EMM Loans denies it did anything wrong.

BMW Shark Fin Antenna Sealing Defect Settlement

BMW manufactured certain 2019-2020 BMW X3, X4, X5, X6, and X7 vehicles with a shark-fin antenna that had sealing defects. The settlement requires BMW to reimburse owners and lessees for past repair costs related to this defect and extend the New Vehicle Limited Warranty coverage for the sealing defect.

Reimbursement for eligible past Sealing-Defect Repair expenses and extension of New Vehicle Limited Warranty

Labcorp Data Breach Settlement

Labcorp allegedly suffered a data breach involving customer diagnostic services information through American Medical Collection Agency. The company has agreed to settle for $35 million related to this alleged security breach.

NJ Bureau of Securities Settlement with Credit Suisse

Credit Suisse allegedly violated New Jersey Securities Law by making materially false and misleading statements regarding RMBS trust certificates and engaging in fraudulent practices. On October 24, 2022, the court entered a consent order requiring Credit Suisse to pay $300 million in restitution to investors. Credit Suisse neither admitted nor denied the allegations.

Eagle Pharma Securities Litigation Settlement

Eagle Pharmaceuticals, Inc. is the subject of a securities litigation class action. Shareholders who purchased the company's publicly traded common stock between August 9, 2022 and October 1, 2024 allege claims covered by this settlement, which the defendant has agreed to settle.